Myriad Genetics’ Australian Cancer Gene Patents Go on Trial in Sydney, Australia - Bloomberg

recruiting: The Molecular Predisposition to (Lynch Syndrome) (HNPCC) - ClinicalTrials.gov - see Blogger's Notes on this trial

Blogger's Note:  

this trial does not include a spectrum of Lynch Syndrome-associated cancers such as; ovarian, brain, pancreatic - all high mortality rate cancers except research indicates that those with genetic syndromes (in general) have improved survival rates; there may be a connection as to what and what has not been included (cancer sites) as this is a 15 yr observational study; however, if interested in participating, the contact information is below; it would be interesting to understand the (exclusion by default) inclusion rationale and in particular relating to those of the  rarer cancer sites in Lynch Syndrome
    ~~~~~~~~~~~~~~~~~~~~~~~~

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

This study is currently recruiting participants.

Verified December 2011 by M.D. Anderson Cancer Center

First Received on October 4, 2011. Last Updated on December 20, 2011 History of Changes

Please refer to this study by its ClinicalTrials.gov identifier: NCT01447199

Contact: Patrick Lynch, MD, JD

713-794-5073

Purpose

The goal of this study is to understand factors which may influence risk for colorectal and other cancers in families. These factors include genetic variability, in combination with diet and lifestyle. In order to achieve these goals, the investigators need to contact as many eligible participants as possible.

This study proposes to identify genetic risk factors that predispose to colorectal cancer (CRC). The focus of this study will be to understand the role of the mismatch repair genes responsible for Hereditary Non-polyposis Colorectal Cancer (HNPCC), i.e., hMSH2, hMLH1 and other mismatch repair genes and modifier genes in combination with diet and lifestyle in familial and de novo colon cancer cases. By examining the status of the mismatch repair genes in both normal and neoplastic tissues among mismatch repair gene mutation carriers, family members not carrying the mutation and non-HNPCC families, it will be possible to determine the role of the mismatch repair genes in the development of colon cancer within HNPCC families.

Condition	Intervention
Bladder Cancer Colorectal Cancer Endometrial Cancer Kidney Cancer Skin Cancer Uterus Cancer	Behavioral: Health and Diet Questionnaire

not yet recruiting: A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 - Full Text View - ClinicalTrials.gov

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

This study is not yet open for participant recruitment.

Verified February 2012 by Duke University

First Received on January 24, 2012. Last Updated on February 1, 2012 History of Changes

Sponsor:	Duke University
Collaborator:	Department of Defense
Information provided by (Responsible Party):	Duke University
ClinicalTrials.gov Identifier:	NCT01526473

Purpose

HER2 is a protein that is over expressed in 20-30% of breast cancers. It is also found associated with lung, gastric, ovarian, and pancreatic cancers. Although there are existing therapies that can target HER2, most patients will eventually experience progression of their disease even though their cancer continues to express HER2. Therefore, new approaches are needed for treating tumors that express HER2.

This clinical trial will use an investigational cancer vaccine called HER2 VRP or AVX901. The vaccine is based on a virus called Venezuelan equine encephalitis but it has been changed so it cannot cause active infection. Instead, the virus has been changed so it tells the immune system to attack cancer cells which make HER2.

The objectives of the study are to evaluate the safety of immunization with HER2 VRP in patients with advanced or metastatic malignancies that express HER2, and to test whether immunization will causes a strong immune system attack against the cancer.

Condition	Intervention	Phase
HER2+ Cancer	Biological: AVX901	Phase I

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label
Official Title:	A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer - Full Text View - ClinicalTrials.gov

This study is currently recruiting participants.

Verified January 2012 by Memorial Sloan-Kettering Cancer Center

First Received on November 10, 2011. Last Updated on January 30, 2012 History of Changes

Sponsor:	Memorial Sloan-Kettering Cancer Center
Information provided by (Responsible Party):	Memorial Sloan-Kettering Cancer Center ( Memorial Sloan-Kettering Cancer Center )
ClinicalTrials.gov Identifier:	NCT01471483

Purpose

Older woman with ovarian cancer have a worse prognosis compared to younger patients. However, the reason is not known. Currently, the standard of care is to evaluate younger and older patients with cancer the same way. However, older patients with cancer often have more complicated issues to manage. For example, older patients often have other medical problems, take more medications, and be dependent on others for help and transportation. Too often, the medical team is unaware of these issues which can effect the patients care.

The purpose of this study is to apply a set of questions designed specifically for patients with cancer who are older than 65 years of age. These questions are called a geriatric assessment.

The investigators want to better understand which older patients with ovarian cancer will be able to tolerate the chemotherapy and surgery and why. This study will also see if a telephone call from a nurse who specializes in caring for older patients will improve patient care. This study will determine how feasible it is to perform geriatric assessments and telephone calls in patients with ovarian cancer.

Condition	Intervention
Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer	Behavioral: geriatric assessment and telephone call from nurse Other: geriatric assessment and no call from nurse

Study Type:

Observational

AACR-SU2C Clinical Trials Finder